Allergology International (Apr 2017)

Autoantibody profiles and their association with blood eosinophils in asthma and COPD

  • Koji Tamai,
  • Harukazu Yoshimatsu,
  • Toshiharu Saito,
  • Hirofumi Matsuoka,
  • Nobuhiko Okada,
  • Yasuko Koma,
  • Akiko Otsuka,
  • Nao Oda,
  • Sayaka Inoue,
  • Sachie Kume,
  • Yujiro Suzuki

DOI
https://doi.org/10.1016/j.alit.2016.08.005
Journal volume & issue
Vol. 66, no. 2
pp. 332 – 337

Abstract

Read online

Background: Autoimmune involvement in the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD) has been proposed, and autoantibodies are a hallmark of autoimmunity. This study aimed to compare the autoantibody profiles of asthma and COPD, and the relationship between autoantibodies and features of these diseases. Methods: We recruited 110 asthma patients and 92 COPD patients for a prospective study. Six autoantibody types were evaluated: antinuclear antibody, anti-cytoplasmic antibodies, rheumatoid factor, anti-cyclic citrullinated peptide antibody, myeloperoxidase–anti-neutrophil cytoplasmic autoantibody (MPO-ANCA) and proteinase 3-ANCA. Other clinical data were also recorded concurrently. Results: An antinuclear antibody titre of ≥1:160 presented only in asthma but not in COPD (10% vs. 0%, p = 0.0002). Eosinophil counts in blood were negative predictors of antinuclear antibody in asthma. Conversely, eosinophil counts in blood and immunoglobulin-E levels of ≥100 IU/mL were positively associated with rheumatoid factor in asthma but not in COPD. There was no relationship between antinuclear antibody or rheumatoid factor and disease severity. Conclusions: It is possible that asthma tends to involve autoimmunity associated with antinuclear antibody more frequently than COPD because asthma is the more robust factor for antinuclear antibody positivity. Antinuclear antibody and rheumatoid factor are associated with eosinophilic responses, but they do not work as biomarkers for disease severity.

Keywords